๐ก Gut dysbiosis is implicated in various chronic diseases, including obesity, inflammatory bowel disease, and cancer. This scoping review explores the effects of tocotrienol, a subfamily of vitamin E, on gut microbiota, drawing insights from six relevant preclinical studies.
๐ Key Findings:
๐ Effect on Gut Microbiota Composition: Tocotrienol demonstrated the ability to alter the composition of gut microbiota in animal models. The studies induced diseases associated with gut dysbiosis, and tocotrienol partially restored the gut microbiota compositions of diseased rats, resembling those of healthy rats.
๐ Anti-inflammatory Effects: Tocotrienol exhibited strong anti-inflammatory effects in animal models with induced diseases. The modulation of gut microbiota by tocotrienol appeared to contribute to its anti-inflammatory properties.
๐ Associations with Disease Models: Tocotrienol has shown promise in preventing or reversing diseases such as colitis-associated colon cancer, obesity, and non-alcoholic fatty liver disease by correcting associated gut dysbiosis.
๐ Bidirectional Relationship with Gut Microbiota: Tocotrienol not only influences the gut microbiota but is also metabolized by it. Studies suggest that the presence of gut microbiota may decrease tocotrienol’s bioavailability.
Tocotrienol appears to counteract dysbiosis and associated immune dysregulation, as evidenced by its impact on the F/B ratio and abundance of specific bacterial phyla. The bidirectional relationship between tocotrienol and gut microbiota necessitates further investigation, especially regarding ways to enhance tocotrienol bioavailability without disrupting gut microbiota balance.
Link to the article : https://tinyurl.com/2ru7ffas
